Lv3
210 积分 2021-08-25 加入
Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB–IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial
2小时前
已完结
Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial
11天前
已完结
Clinical characteristics and prognostic value of the KRAS mutation in Chinese colorectal cancer patients
12天前
已完结
Tislelizumab Versus Docetaxel in Patients With Previously Treated Advanced NSCLC (RATIONALE-303): A Phase 3, Open-Label, Randomized Controlled Trial
22天前
已完结
Three-year follow-up and patient-reported outcomes from CheckMate 078: Nivolumab versus docetaxel in a predominantly Chinese patient population with previously treated advanced non-small cell lung cancer
22天前
已完结
Combinatorial strategies to target RAS-driven cancers
27天前
已完结
Garsorasib in patients with KRASG12C-mutated non-small-cell lung cancer in China: an open-label, multicentre, single-arm, phase 2 trial
27天前
已完结
D-1553 (Garsorasib), a Potent and Selective Inhibitor of KRASG12C in Patients With NSCLC: Phase 1 Study Results
27天前
已完结
Discovery of MK-1084: An Orally Bioavailable and Low-Dose KRASG12C Inhibitor
27天前
已完结
皖公网安备34019202002308
